We are excited to announce Przemek Obloj has joined bit bio as our new Chief Financial Officer! With two decades of financial and investment expertise in health, life sciences, and technology sectors, Przemek will oversee our financial strategy and capital fundraising efforts. He will work closely with our Founder and CEO, Mark Kotter, to drive bit.bio continued growth and innovation. Przemek's impressive track record and global investment expertise will be instrumental in scaling our operations and advancing our position as a global leader in cell programming. We are delighted to have his energy and leadership driving continued success at bit.bio. Please join us in welcoming Przemek to our team! See our press release for more information. https://hubs.ly/Q02Jx7GK0 #PrzemekObloj #CFO #bitbio #CellProgramming #IPSC #CellTherapy #SyntheticBiology #SynBio #BioTech
bit.bio
Biotechnology Research
Cambridge, Cambridgeshire 18,501 followers
The Cell Coding Company
About us
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks
- Website
-
https://bit.bio
External link for bit.bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Privately Held
- Founded
- 2016
- Specialties
- biotechnology, cell type, life science, pharmaceutical drug discovery, High throughput screening, and cell therapy
Locations
-
Primary
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge, Cambridgeshire CB22 3FH, GB
Employees at bit.bio
Updates
-
Are you developing drugs for neurodegenerative diseases? How important is it to reduce risk during your target identification? By using a defined iPSC derived model which accurately and consistently represents human biology for your target identification, rather than an immortalised cell line, you can improve the chance your drug will translate effectively into clinical trials. CRISPR Ready ioCells allow you to conduct efficient gene knockouts and CRISPR screens in highly consistent human CNS cells as easily and routinely as similar experiments in immortalised cell lines, but in relevant human cell types. Want to find out more? https://hubs.ly/Q02MlqGD0 #research #DrugDiscovery #CRISPR #CRISPRscreens #TargetID #ioCells #optiox
-
-
🥇 A world 1st! For the first time, our newly expanded opti-ox powered CRISPR-Ready ioCells toolkit gives you off-the-shelf access to functional human iPSC-derived microglia and glutamatergic neurons, built for the easy and routine generation of gene knockouts and CRISPR screens. Even if this is your first time using CRISPR or iPSC-derived cells, you can use CRISPR-Ready ioCells with our optimised protocols to start obtaining readouts in a matter of days. Everything is optimised for you. Discover the cells: https://hubs.ly/Q02M3pPw0 #research #DrugDiscovery #CRISPR #CRISPRscreens #TargetID #ioCells #optiox
-
-
🚨WEBINAR ALERT! 🚨 A unique opportunity to deepen your understanding of astrocytes and their crucial role in the CNS. Our 2 expert speakers will explore the roles of astrocytes in the human brain and discuss how targeting these cells could transform therapeutic strategies that traditionally focus predominantly on neurons. Save the date and register now: https://hubs.ly/Q02LVpFJ0 Thomas Brown, Jeremy Krohn, Charité - Universitätsmedizin Berlin, German Center for Neurodegenerative Diseases (DZNE) #Neuroscience #Glia #CNS #NeuroDegenerativeDisease #bitbio #BrainResearch #CellManufacturing #optiox
-
-
📆 Mark your calendars for September 5th. We’re bringing together two experts for a scientific discussion on cutting-edge CRISPR technologies. Join us and hear from Luke Gilbert, Associate Professor at University of California, San Francisco and Sejla Salic-Hainzl, VP of R&D at bit.bio, as they cover the latest tools powering the next generation of physiologically relevant CRISPR screens. Discover groundbreaking research on scalable screens designed for the characterisation of genes and gene regulatory elements within the human genome. Plus, dive into the latest data on innovative iPSC-derived cell technologies, developed to make gene knockouts and CRISPR screens more efficient and routine in physiologically relevant models. Secure your spot on Technology Networks now! Register here: https://hubs.ly/Q02LH6NQ0 #research #DrugDiscovery #CRISPR #CRISPRscreens #TargetID #ioCells #optiox
-
-
Neuroscientists: Co-culture ready human iPSC-derived ioAstrocytes are available now. Simplify lab work for CNS co-cultures, shorten optimisation timelines and focus on your scientific questions with our co-culture protocols. Now complex experimental setups become easy to navigate. Learn more about our ioAstrocytes & ioGlutamatergic Neurons co-culture protocol: https://hubs.ly/Q02Lj1Gl0 #neuroscience #CNSResearch #neurodegeneration #DrugDiscovery #astrocytes #ioCells #optiox
-
-
Scientists at Inventia Life Science were challenged by their collaborator to generate a 3D neuronal model that closely resembled the human brain, was scalable to 96 well formats, was assay-ready, and was consistent enough to deploy across multiple labs. No small task! Inventia achieved this by combining ioGlutamatergic Neurons from https://hubs.ly/Q02Lj4Rv0 with iPSC-derived astrocytes, printed together in a 3D matrix using Inventia’s RASRTUM platform. As a result, their collaborator was able to build new drug discovery assays with improved physiological relevance. Watch the webinar on-demand to discover how: https://hubs.ly/Q02Lj8BR0
-
-
We are excited to see glia—long overshadowed by neurons—taking centre stage in the latest issue of Nature Neuroscience. This special issue highlights how research into these dynamic, multifaceted cells is transforming our understanding of the brain. Neuroscience has traditionally focused on neurons, but as glial research has advanced, scientists have learned that glia play crucial roles in brain function, from memory and learning to neurodegenerative diseases. The rapid pace of discovery in this field is exhilarating, and the new insights are challenging old paradigms, revealing just how integral glia are to the nervous system. 🔍 Dive into the special issue of Nature Neuroscience to explore the paradigm shift that's reshaping the field. https://hubs.ly/Q02Lf7wt0 🎓 To deepen your understanding of astrocytes and the crucial role of these glia cells in the CNS, we also have a webinar coming up that you can now register for. https://hubs.ly/Q02Lf8pK0 #Neuroscience #Glia #Innovation #bitbio #NatureNeuroscience #BrainResearch #CellManufacturing, #optiox, Nature Portfolio
-
-
Anyone with experience in a neuronal cell culture lab probably remembers that one person who could consistently produce perfect confluent cell cultures that never clumped or disassociated. What is their secret? In our newly published blog we interview Christopher Aruthan, our expert in GABAergic neuron cell culture. They share 4 cell culture hacks that they use to ensure problem-free cultures of iPSC-derived GABAergic neurons in every experiment. Read the interview: https://hubs.ly/Q02L4Gvf0 #neuroscience #labtips #cellculture #research #iocells #GABAergicneurons #researchmethods
-
-
bit.bio reposted this
🚀 Back on 18th June, HURUN UK had the thrill of visiting the cutting-edge bit.bio labs in Cambridge! 🌟 bit.bio is one of the 38 UK companies that made it onto Hurun’s 2023 Global Cheetah list. This prestigious list highlights start-ups most likely to achieve unicorn status ($1bn valuation) within five years. 🏢 A University of Cambridge spin-out, bit.bio was founded by Mark Kotter and Florian Schuster. This innovative synthetic biology company is revolutionising biomedical research and treatments. It is democratising human cells to advance biomedical research (SDG9) and enable transformative treatments (SDG3). Their Nobel Prize-winning science and unique opti-ox enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This technology allow for the rapid, industrial-scale production of any human cell type from induced pluripotent stem cells (iPSCs) with unmatched purity and consistency. 🔬 Bit.bio is creating highly differentiated human cell products for research of drug recovery (ioCells) and cell therapy (txCells). Their impressive ioCells portfolio includes ioWild Type Cells, ioDisease Model Cells, and ioCRISPR-Ready Cells. Their cell therapy pipeline targets metabolism, endocrinology, immunology, and neurology, with a leading candidate, bbHEP01, in development for acute liver diseases. They are also collaborating with BlueRock Therapeutics on reugulatory T cell (Treg)-based cell therapies. 💰 Since its launch in 2016, bit.bio has raised approximately $200m from top-tier investors, including Arch Venture, BlueYard Capital, Charles River Laboratories, Foresite Capital, Milky Way, National Resilience, and Tencent. 🚀 We’re eagerly following bit.bio’s journey and are confident they’re on the path to achieving unicorn status soon. Keep an eye on this game-changer in synthetic biology! Later this year, Hurun will release the Global Cheetah list 2024 and Global Gazelle list 2024. Gazelles are start-ups founded in the 2000s, worth over US$500mn, not yet listed on a public exchange and most likely to ‘go unicorn’, ie hit a valuation of US$1bn, within three years. 📈 Check out the full 2023 Global Cheetah list here: https://lnkd.in/e4xgGTMW 📈 Explore Hurun’s 2024 Global Unicorn Index here: https://lnkd.in/e5iKktpA #SyntheticBiology #Innovation #Biotech #Hurun #GlobalCheetah #UnicornStatus #BiomedicalResearch #Startups #Investment #CambridgeBiotech
-